{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T04:32:00Z","timestamp":1786422720721,"version":"build-2736575974"},"reference-count":52,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>\n                    <jats:italic>TP53<\/jats:italic>\n                    -mutated myeloid neoplasms, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), remain among the hardest-to-treat hematologic malignancies, with short survival despite hypomethylating agents +\/- venetoclax, and allogeneic transplantation. Despite encouraging early-phase data, Phase 3 trials of mutant-p53 reactivators to date have not yet translated into clear, practice-changing survival benefits, highlighting a need to explore complementary strategies that aim to directly restore wild-type p53 function in the leukemic niche. Building on clinical experience with the adenoviral p53 product (rAd-p53) in solid tumors, where intratumoral rAd-p53 achieves high cumulative response rates with manageable toxicity, we investigate the feasibility of translating p53 replacement into select\n                    <jats:italic>TP53<\/jats:italic>\n                    -mutated myeloid neoplasms using antigen-directed delivery systems. Advances in AML surface proteomics and immunotherapy identify many antigens of interest, in particular, CD33, CD123, and CD209, as internalizing myeloid antigens that are broadly expressed on leukemic blasts and stem\/progenitor cells. In parallel, emerging data on\n                    <jats:italic>in vivo<\/jats:italic>\n                    gene delivery via lipid nanoparticles (LNP) and adenovirus platforms that are capable of efficient marrow transduction demonstrate that systemic gene transfer to hematopoietic compartments is feasible. We outline a framework in which CD33-, CD123-, and CD209-directed mRNA\/LNP systems or leukemia-adapted rAd-p53 vectors could potentially be used to restore wild-type\n                    <jats:italic>TP53<\/jats:italic>\n                    in\n                    <jats:italic>TP53<\/jats:italic>\n                    -mutant myeloid clones and discuss key preclinical questions in xenograft models. We acknowledge that the strategy is built on converging but largely indirect lines of evidence rather than direct experimental data in\n                    <jats:italic>TP53<\/jats:italic>\n                    -mutated AML\/MDS, and we explicitly discuss key preclinical validation requirements and biological barriers, including dominant-negative stoichiometry, liver sequestration, and by conceivable toxicities, that must be systematically addressed before clinical translation.\n                  <\/jats:p>","DOI":"10.3389\/fonc.2026.1874395","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T04:21:28Z","timestamp":1786422088000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Antigen-directed p53 restoration in TP53-mutated myeloid neoplasms: a hypothesis and theory perspective"],"prefix":"10.3389","volume":"16","author":[{"given":"Georgio","family":"Medawar","sequence":"first","affiliation":[{"name":"Department of Hematology-Oncology, Medical University of South Carolina","place":["Charleston, SC, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadie","family":"Pyle","sequence":"additional","affiliation":[{"name":"College of Pharmacy and Pharmaceutical Sciences, University of Toledo","place":["Toledo, OH, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praneeth","family":"Baratam","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, Medical University of South Carolina","place":["Charleston, SC, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Coltoff","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, Medical University of South Carolina","place":["Charleston, SC, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1002\/ajh.27655","article-title":"TP53-mutated myeloid neoplasms: 2024 update on diagnosis, risk-stratification, and management","volume":"100","author":"Shah","year":"2025","journal-title":"Am J Hematol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025029691","article-title":"A clinical guide to TP53 mutations in myeloid neoplasms","volume":"146","author":"Urrutia","year":"2025","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.283886","article-title":"Outcome heterogeneity of TP53-mutated myeloid neoplasms and the role of allogeneic hematopoietic cell transplantation","volume":"109","author":"Pasca","year":"2024","journal-title":"Haematologica"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1655486","article-title":"TP53-mutated MDS and AML: immune dysregulation, tumor microenvironment, and emerging therapeutic strategies","volume":"15","author":"Albakri","year":"2025","journal-title":"Front Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s13045-021-01169-0","article-title":"Targeting mutant p53 for cancer therapy: direct and indirect strategies","volume":"14","author":"Hu","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00265-4","article-title":"Current status of phase 3 clinical trials in high-risk myelodysplastic syndromes: pitfalls and recommendations","volume":"10","author":"Garcia-Manero","year":"2023","journal-title":"Lancet Haematol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/s41419-018-0463-7","article-title":"APR-246 reactivates mutant p53 by targeting cysteines 124 and 277","volume":"9","author":"Zhang","year":"2018","journal-title":"Cell Death Dis"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025028935","article-title":"Restoring p53 wild-type conformation in TP53-Y220C\u2013mutant acute myeloid leukemia","volume":"146","author":"Carter","year":"2025","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41368-021-00145-1","article-title":"Expert consensus on the clinical application of recombinant adenovirus human p53 for head and neck cancers","volume":"13","author":"Li","year":"2021","journal-title":"Int J Oral Sci"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.2147\/dddt.s3535","article-title":"Gene medicine for cancer treatment: commercially available medicine and accumulated clinical data in China","volume":"2","author":"Ma","year":"2009","journal-title":"Drug Des Devel Ther"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2023.101155","article-title":"Twenty years of Gendicine\u00ae rAd-p53 cancer gene therapy: The first-in-class human cancer gene therapy in the era of personalized oncology","volume":"11","author":"Qi","year":"2024","journal-title":"Genes Dis"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-018-1932-2","article-title":"Evaluation of safety and efficacy of p53MVA vaccine combined with pembrolizumab in patients with advanced solid cancers","volume":"21","author":"Chung","year":"2019","journal-title":"Clin Transl Oncol Off Publ Fed Spanish Oncol Soc Natl Cancer Inst Mex"},{"key":"B13","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1038\/s41467-022-28279-8","article-title":"Combining p53 mRNA nanotherapy with immune checkpoint blockade reprograms the immune microenvironment for effective cancer therapy","volume":"13","author":"Xiao","year":"2022","journal-title":"Nat Commun"},{"key":"B14","doi-asserted-by":"publisher","first-page":"107041","DOI":"10.1016\/j.leukres.2023.107041","article-title":"Recombinant human p53 adenovirus injection combined with Bortezomib inhibits proliferation and promotes apoptosis in multiple myeloma","volume":"127","author":"Wang","year":"2023","journal-title":"Leuk Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/ijms262210818","article-title":"Molecular and clinical insights into TP53-mutated MDS and AML","volume":"26","author":"Georgantzinos","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-22-0332","article-title":"TP53-mutated myelodysplastic syndrome and acute myeloid leukemia: biology, current therapy, and future directions","volume":"12","author":"Daver","year":"2022","journal-title":"Cancer Discov"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-24-1136","article-title":"The prolonged half-life of the p53 missense variant R248Q promotes accumulation and heterotetramer formation with wild-type p53 to exert the dominant-negative effect","volume":"85","author":"Klemm","year":"2025","journal-title":"Cancer Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00863.x","article-title":"Molecular cloning and functional analysis of the CD33 promoter","volume":"102","author":"Bodger","year":"1998","journal-title":"Br J Haematol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"5944","DOI":"10.1002\/hem3.70332","article-title":"Unraveling TP53-mutated acute myeloid leukemia: clinical insights and genetic profiles","volume":"144","author":"Park","year":"2024","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-023-05384-2","article-title":"Reliability of flow-cytometry in diagnosis and prognostic stratification of myelodysplastic syndromes: correlations with morphology and mutational profile","volume":"102","author":"Guarnera","year":"2023","journal-title":"Ann Hematol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.429","article-title":"Induction treatment of acute myeloid leukemia in an elderly patient with intramarrow injection\/administration of cytarabine: first report of a case","volume":"3","author":"Islam","year":"2015","journal-title":"Clin Case Rep"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.1081","article-title":"Induction treatment of acute myeloid leukemia in an elderly patient with intramarrow injection\/administration of cytarabine. Second case report","volume":"5","author":"Islam","year":"2017","journal-title":"Clin Case Rep"},{"key":"B23","doi-asserted-by":"publisher","first-page":"101436","DOI":"10.1016\/j.omtm.2025.101436","article-title":"Why do lipid nanoparticles target the liver? Understanding of biodistribution and liver-specific tropism","volume":"33","author":"Hosseini-Kharat","year":"2025","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2024.101402","article-title":"Reducing off-target expression of mRNA therapeutics and vaccines in the liver with microRNA binding sites","volume":"33","author":"Parrett","year":"2025","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.123.065438","article-title":"MicroRNA-122\u2013mediated liver detargeting enhances the tissue specificity of cardiac genome editing","volume":"149","author":"Yang","year":"2024","journal-title":"Circulation"},{"key":"B26","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3322\/caac.21873","article-title":"Acute myeloid leukemia management and research in 2025","volume":"75","author":"Kantarjian","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024262","article-title":"How I treat blastic plasmacytoid dendritic cell neoplasm","volume":"145","author":"Kharfan-Dabaja","year":"2025","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024063","article-title":"Honing CAR T cells to tackle acute myeloid leukemia","volume":"145","author":"Haubner","year":"2025","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2014.39","article-title":"Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia","volume":"4","author":"Ehninger","year":"2014","journal-title":"Blood Cancer J"},{"key":"B30","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1097\/ppo.0000000000000577","article-title":"Monoclonal antibodies in acute myeloid leukemia-are we there yet","volume":"28","author":"Abaza","year":"2022","journal-title":"Cancer J"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1016\/j.stem.2024.09.003","article-title":"Epitope prime editing shields hematopoietic cells from CD123 immunotherapy for acute myeloid leukemia","volume":"31","author":"Ji","year":"2024","journal-title":"Cell Stem Cell"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1819992116","article-title":"Gene-edited stem cells enable CD33-directed immune therapy for myeloid Malignancies","volume":"116","author":"Borot","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-20-2149","article-title":"Development of highly optimized antibody-drug conjugates against CD33 and CD123 for acute myeloid leukemia","volume":"27","author":"Han","year":"2021","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20231235","article-title":"Epitope-engineered human hematopoietic stem cells are shielded from CD123-targeted immunotherapy","volume":"220","author":"Marone","year":"2023","journal-title":"J Exp Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06496-5","article-title":"Epitope editing enables targeted immunotherapy of acute myeloid leukaemia","volume":"621","author":"Casirati","year":"2023","journal-title":"Nature"},{"key":"B36","doi-asserted-by":"publisher","first-page":"3471","DOI":"10.1182\/blood-2024-211815","article-title":"Development of a UM171-supported, CD33 epitope-engineered blood stem cell graft for advanced AML therapies","volume":"144","author":"Lehnertz","year":"2024","journal-title":"Blood"},{"key":"B37","doi-asserted-by":"publisher","first-page":"102542","DOI":"10.1016\/j.nantod.2024.102542","article-title":"CD33 targeted EzH1 regulated nanotherapy epigenetically inhibits fusion oncoprotein (AML1-ETO) rearranged acute myeloid leukemia in both in vitro and in vivo patient derived xenograft models","volume":"59","author":"Kushwaha","year":"2024","journal-title":"Nano Today"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24032718","article-title":"CD123 a therapeutic target for acute myeloid leukemia and blastic plasmocytoid dendritic neoplasm","volume":"24","author":"Pelosi","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12113087","article-title":"CD123 as a biomarker in hematolymphoid Malignancies: principles of detection and targeted therapies","volume":"12","author":"El Achi","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.70019","article-title":"CD123-targeting immunotherapeutic approaches in acute myeloid leukaemia","volume":"207","author":"Dreyzin","year":"2025","journal-title":"Br J Haematol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011858","article-title":"Dual-targeting CD33\/CD123 NANOBODY T-cell engager with potent anti-AML activity and good safety profile","volume":"8","author":"Zeng","year":"2024","journal-title":"Blood Adv"},{"key":"B42","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1182\/blood-2025-385","article-title":"Unbiased in-depth surfaceome profiling of acute myeloid leukemia reveals novel immunotherapy targets beyond canonical membrane proteins","volume":"146","author":"Barpanda","year":"2025","journal-title":"Blood"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2008.56","article-title":"Dermal dendritic cells\u201d comprise two distinct populations: CD1+ dendritic cells and CD209+ macrophages","volume":"128","author":"Ochoa","year":"2008","journal-title":"J Invest Dermatol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1021\/acs.nanolett.3c00304","article-title":"In vivo RNA delivery to hematopoietic stem and progenitor cells via targeted lipid nanoparticles","volume":"23","author":"Shi","year":"2023","journal-title":"Nano Lett"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/s41565-024-01847-3","article-title":"Nature-inspired platform nanotechnology for RNA delivery to myeloid cells and their bone marrow progenitors","volume":"20","author":"Hofstraat","year":"2025","journal-title":"Nat Nanotechnol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1182\/blood-2024-208626","article-title":"In vivo HSC gene editing for correction of the sickle cell mutation using RNA gene writers","volume":"144","author":"Tozzi","year":"2024","journal-title":"Blood"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-LBA-1","article-title":"Minimal residual disease (MRD)-negative outcomes following a novel, in vivo gene therapy generating anti\u2013B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cells in patients with relapsed and refractory multiple myeloma (RRMM): preliminary","volume":"146","author":"Harrison","year":"2025","journal-title":"Blood"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1002\/1873-3468.13668","article-title":"Adenovirus vectors in hematopoietic stem cell genome editing","volume":"593","author":"Li","year":"2019","journal-title":"FEBS Lett"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3390\/v2102290","article-title":"Tropism-modification strategies for targeted gene delivery using adenoviral vectors","volume":"2","author":"Coughlan","year":"2010","journal-title":"Viruses"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2014.15","article-title":"CD123 targeting oncolytic adenoviruses suppress acute myeloid leukemia cell proliferation in vitro and in vivo","volume":"4","author":"Li","year":"2014","journal-title":"Blood Cancer J"},{"key":"B51","doi-asserted-by":"publisher","first-page":"7017","DOI":"10.1038\/s41467-025-61449-y","article-title":"GFP-on mouse model for interrogation of in vivo gene editing","volume":"16","author":"Dib","year":"2025","journal-title":"Nat Commun"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2024.285000","article-title":"Prognostic impact of \u2018multi-hit\u2019 versus \u2018single-hit\u2019 TP53 alteration in patients with acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases","volume":"109","author":"Badar","year":"2024","journal-title":"Haematologica"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1874395\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T04:21:29Z","timestamp":1786422089000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1874395\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,11]]},"references-count":52,"alternative-id":["10.3389\/fonc.2026.1874395"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1874395","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,11]]},"article-number":"1874395"}}